What category does this event fall under?

Business — classified as stock offering.

What is the sentiment of coverage?

Aggregate sentiment score: 0 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

China Pharma Holdings priced offering · FT Global Capital acted as placement agent China Pharma Holdings

Is this event still developing?

This is an active story, last updated Jul 23, 2026. Coverage continues to evolve.

Business stock offering

China Pharma $5M Direct Offering

Q: When did this event occur?

First reported Jul 22, 2026; last updated Jul 23, 2026.

Q: Who was involved?

Top entities: China Pharma Holdings, FT Global Capital, United States — United States Securities and Exchange Commission, Hainan Helpson Medical & Biotechnology.

Q: What is the market impact?

General. The offering provides China Pharma with $5 million in working capital, which may support operations but also dilutes existing shareholders.

Analysis based on 7 articles · First reported Jul 22, 2026 · Last updated Jul 23, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The offering provides China Pharma with $5 million in working capital, which may support operations but also dilutes existing shareholders. The small size and routine nature of the offering are unlikely to have a significant impact on broader markets.

Pharmaceuticals

Event Summary

China Pharma Holdings, Inc. (NYSE American: CPHI) announced the pricing and closing of a registered direct offering of 2.5 million shares of common stock at $2.00 per share, raising gross proceeds of $5 million. The offering closed on July 23, 2026. FT Global Capital, Inc. acted as exclusive placement agent. Net proceeds will be used for working capital and general corporate purposes. The offering was made under an effective shelf registration statement filed with the SEC.

Key Actions

100 China Pharma Holdings priced offering

30 FT Global Capital acted as placement agent China Pharma Holdings

Entities Involved

stock

China Pharma Holdings

China Pharma raised $5 million through a direct offering, providing working capital but diluting existing shareholders.

Importance 100.0 Sentiment -10.0

priv

FT Global Capital

FT Global Capital acted as exclusive placement agent for the offering, earning fees.

Importance 20.0 Sentiment 0.0

govactor

United States — United States Securities and Exchange Commission

The SEC reviewed and declared effective the shelf registration statement used for the offering.

Importance 10.0 Sentiment 0.0

priv

Hainan Helpson Medical & Biotechnology

Hainan Helpson is a wholly-owned subsidiary of China Pharma, not directly involved in the offering.

Importance 5.0 Sentiment 0.0

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard